omniture

Synutra Reports Fourth Quarter and Full Year Fiscal 2011 Financial Results

2011-06-15 04:35 1988

Inventory Trends Reflect Sustained Recovery

4Q11 Net Sales Up 79.3% from 3Q11

Fiscal 2011 Gross Margin Increased to 31.3%

QINGDAO, China and ROCKVILLE, Md., June 15, 2011 /PRNewswire-Asia/ -- Synutra International, Inc. (NASDAQ: SYUT), a leading infant formula company in China and a producer, marketer and seller of nutritional products for infants, children and adults, today announced financial results for the fourth quarter and full year of fiscal 2011 ended March 31, 2011.

Mr. Liang Zhang, Chairman and CEO of Synutra, remarked, "Our results this quarter demonstrate that our recovery is ongoing and, we believe, sustainable. Sales of our branded powdered formula have doubled since the last quarter, led by growth of our Super series. Furthermore, we have launched a new brand, our My Angel series, to capitalize on the shifting market dynamics of China's infant dairy market. This supplementary product line will be distributed through specialty baby stores with unique formulations and is not expected to cannibalize our existing premium product lines. Looking forward, we believe our focus on premium quality brands as well as our broadening distribution reach will lead to greater consumer recognition."

Mr. Donghao Yang, Chief Financial Officer of Synutra, commented, "The fourth quarter is also significant from a channel perspective. We have begun to see signs of our distributors' inventory levels stabilizing after the destocking in the previous two quarters. Overall, we are pleased with the continued financial and operational improvements accomplished by our dedicated employees."

Financial Results for the Fourth Quarter of Fiscal 2011 versus Third Quarter of Fiscal 2011


 

 

 

Quarter Ended

 

 

QoQ Change

 

 

 

March 31, 2011

 

December 31, 2010

 

 

USD 000's

 

(%)

 

 

Net sales

 

79,294

 

44,233

 

 

35,061

 

79.3%

 

 

 

 

 

 

 

 

 

Cost of sales

 

(61,826)

 

(39,211)

 

 

(22,615)

 

57.7%

 

 

Gross profit

 

17,468

 

5,022

 

 

12,446

 

247.8%

 

 

Gross margin

 

22.0%

 

11.4%

 

 

 

 

 

 

 

 

 

 

 

 

Selling and distribution expenses

 

(10,858)

 

(12,714)

 

 

1,856

 

-14.6%

 

 

Advertising and promotion expenses

 

(6,313)

 

(10,451)

 

 

4,138

 

-39.6%

 

 

General and administrative expenses

 

(7,685)

 

(6,130)

 

 

(1,555)

 

25.4%

 

 

Impairment loss of assets disposal

 

0

 

0

 

 

0

 

 

 

Other operating income, net

 

957

 

173

 

 

784

 

453.2%

 

 

Total operating expense

 

(23,899)

 

(29,122)

 

 

(5,223)

 

-17.9%

 

 

 

 

 

 

 

 

 

Loss from operations

 

(6,431)

 

(24,100)

 

 

17,669

 

-73.3%

 

 

Operating margin

 

-8.1%

 

-54.5%

 

 

 

 

 

 

 

 

 

 

 

 

Net interest expense and other income

 

(2,553)

 

(2,366)

 

 

(187)

 

7.9%

 

 

Income tax benefit

 

384

 

5,920

 

 

(5,536)

 

-93.5%

 

 

Net loss attributable to the noncontrolling interest

 

(61)

 

(67)

 

 

(6)

 

-9.0%

 

 

 

 

 

 

 

 

 

Net loss attributable to Synutra International, Inc. common shareholders

 

(8,539)

 

(20,479)

 

 

(11,940)

 

-58.3%

 

 

Net margin

 

-10.8%

 

-46.3%

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share - Diluted

 

($0.15)

 

($0.36)

 

 

$(0.21)

 

-58.3%

 

 

 

 

 

 

 

 

 

 


Net sales increased 79.3% to $79.3 million in the fourth quarter of fiscal 2011 from $44.2 million in the third quarter of fiscal 2011, led by growth in the Company's infant formula sales. Net sales from the Company's branded powdered formula segment were $48.3 million, or 60.9% of net sales in the quarter, compared to $20.7 million, or 46.8% of net sales, in the previous quarter. Net sales of the Company's Super series infant formula accounted for 53.9% of the volume of sales and 65.8% of the net sales of the powdered formula segment for the fourth quarter of fiscal year 2011 compared to 45.4% of the volume of sales and 57.1% of the net sales of the powdered formula segment in the third quarter of fiscal year 2011. By volume, sales of powdered formula products were 6,057 tons in the fiscal fourth quarter compared to 4,063 tons in the previous quarter.

Net sales from Other Products, which mainly consist of surplus milk powder, whey protein and raw milk sold to industrial customers, was $30.8 million, or 38.8% of net sales, in the fourth quarter of fiscal 2011, compared to $23.3 million, or 52.7% of net sales in the third quarter of fiscal 2011. The decrease in sales to industrial customers demonstrates the Company's gradual shift away from distribution of surplus milk powder.

Gross profit was $17.5 million in the fourth quarter of fiscal 2011, compared to $5.0 million in the third quarter of fiscal year 2011. Gross margin in the fourth quarter of fiscal 2011 was 22.0%, compared to 11.4% in the third quarter of fiscal 2011. This reflects the impact of the discounts the Company provided to distributors to regain market share, which were deducted from gross sales, negatively impacting net sales and gross margin.

Loss from operations improved substantially to $6.4 million, from the $24.1 million operating loss in the prior year period. Total operating expenses were 30.1% of revenue reflecting advertising and promotional activities in line with the Company's normalized range.

Mr. Yang continued, "We are pleased to note strong sequential growth in our financial performance. Operating results have shown significant improvement in the fourth quarter compared to the previous two quarters when the hormone crisis impacted results. Our powdered formula segment sales increased by 133.2% and gross margin more than doubled in the fourth quarter compared to the third quarter. Operating loss this quarter narrowed by 73.3% compared with the previous quarter. As we have observed, the destocking of channel inventory is coming to an end, which is a major contributing factor to our operating improvement. As our market share continues to recover directionally over time, distributors will adjust their inventory level upward accordingly, so we expect to see further improvement in our operating results in the coming quarters."


 

 

 

 

Fiscal Year 2011

 

 

 

 

 

First

 

 

 

Second

 

 

 

Third

 

 

 

Fourth

 

 

 

 

 

(In thousands except percentage)

 

 

 

Powdered formula segment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- Net sales

 

 

$

 

79,244

 

 

 

$

 

37,285

 

 

 

$

 

20,722

 

 

 

$

 

48,318

 

 

 

- Gross margin

 

 

 

56.9%

 

 

 

 

28.6%

 

 

 

 

16.1%

 

 

 

 

39.9%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Overall

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

- Income (loss) from operations

 

 

 

16,290

 

 

 

 

(26,101)

 

 

 

 

(24,100)

 

 

 

 

(6,431)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Market Share (last month of each quarter) (CIC data)

 

 

 

7.1%

 

 

 

 

4.6%

 

 

 

 

5.2%

 

 

 

 

4.9%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


Full Year Ended March 31, 2011 Financial Results

Net sales for the fiscal year ended March 31, 2011 decreased 14.9% to $248.5 million from $291.9 million in the prior fiscal year. Net sales from branded powdered formula products decreased 4.5% to $185.6 million, or 74.7% of net sales in the fiscal year ended March 31, 2011, from $194.4 million, or 66.6% of net sales in the prior fiscal year.

Net sales from Other products, which consist mainly of the surplus milk powder to industrial customers, were $61.5 million, or 24.7% of net sales in the fiscal year 2011, compared to $95.2 million, or 32.6% of net sales in the prior fiscal year.

Gross profit was $77.7 million in fiscal year 2011, which decreased 6.8% from $83.4 million in the prior fiscal year. Gross margin increased to 31.3% in fiscal year 2011 from 28.6% in the prior year period.

Operating loss was $40.3 million in fiscal year 2011, compared to an operating loss of $23.9 million in the prior fiscal year. Net loss attributable to Synutra International, Inc. common stockholders was $40.1 million in fiscal year 2011, or ($0.71) per diluted share, compared with a net loss of $24.6 million, or ($0.46) per diluted share in the prior year.

Balance Sheet

As of March 31, 2011, the Company had cash and cash equivalents of $48.7 million and restricted cash of $37.7 million.

Mr. Zhang stated in closing, "We continue to be confident in the long-term potential of both Synutra and China's domestic infant formula market. The past fiscal year has wrought many challenges for both our Company and the broader domestic industry. However, with the government's current focus on quality control as well as our internal dedication to high quality products and a robust nationwide distribution network, we continue to believe the future is bright."

Conference Call Details

The Company will hold a conference call on Wednesday, June 15, 2011 at 8:00 am Eastern Time to discuss the financial results. Listeners may access the call by dialing the following numbers:

United States Toll Free:

 

+1 (866) 405-2350

 

 

International:

 

+1 (718) 354-1231

 

 

Conference ID:

 

72126546

 

 

 

 


The replay will be accessible through June 21, 2011 by dialing the following numbers:

United States Toll Free:

 

+1 (866) 214-5335

 

 

International:

 

+1 (718) 354-1232

 

 

Conference ID:

 

72126546

 

 

 

 


A webcast of the conference call will be available through the Company's IR website at www.synutra.com.

About Synutra International, Inc.

Synutra International, Inc. (Nasdaq: SYUT) is a leading infant formula company in China. It principally produces, markets and sells its products under the "Shengyuan" or "Synutra" name, together with other complementary brands. It focuses on selling premium infant formula products, which are supplemented by more affordable infant formulas targeting the mass market as well as other nutritional products and ingredients. It sells its products through an extensive nationwide sales and distribution network covering 30 provinces and provincial-level municipalities in China. As of March 31, 2011, this network comprised over 580 independent distributors and over 1,000 independent sub-distributors who sell Synutra products in over 71,000 retail outlets.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on our current expectations, assumptions, estimates and projections about Synutra International, Inc. and its industry. All statements other than statements of historical fact in this release are forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as "anticipate," "believe," "continue," "estimate," "expect," "intend," "is/are likely to," "may," "plan," "should," "will," "aim," "potential," "continue," or other similar expressions. The forward-looking statements included in this press release relate to, among others, Synutra's goals and strategies; its future business development, financial condition and results of operations; the expected growth of the nutritional products and infant formula markets in China; market acceptance of Synutra's products; the safety and quality of Synutra's products; Synutra's expectations regarding demand for its products; Synutra's ability to stay abreast of market trends and technological advances; competition in the infant formula industry in China; PRC governmental policies and regulations relating to the nutritional products and infant formula industries, and general economic and business conditions in China. These forward-looking statements involve various risks and uncertainties. Although Synutra believes that the expectations expressed in these forward-looking statements are reasonable, these expectations may turn out to be incorrect. Synutra's actual results could be materially different from the expectations. Important risks and factors that could cause actual results to be materially different from expectations are generally set forth in Synutra's filings with the Securities and Exchange Commission. The forward-looking statements are made as of the date of this press release. Synutra International, Inc. undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date on which the statements are made or to reflect the occurrence of unanticipated events.

FOR FURTHER INFORMATION:

Synutra International, Inc.

 

 

Investor Relations Department

 

 

ir@synutra.com or 301-840-3881

 

 

 




 

 

Synutra International, Inc.

 

 

 

 

 

 

 

 

 

 

 

 

Consolidated Statements of Income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended March 31,

 

 

Year Ended March 31,

 

 

 

 

2011

 

 

2010

 

 

2011

 

 

2010

 

 

2009

 

 

 

(in thousands except earnings per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

 

79,294

 

$

 

82,411

 

$

 

248,516

 

$

 

291,886

 

$

 

312,528

 

 

Cost of sales

 

 

61,826

 

 

43,472

 

 

170,769

 

 

208,476

 

 

259,086

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross profit

 

 

17,468

 

 

38,939

 

 

77,747

 

 

83,410

 

 

53,442

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling and distribution expenses

 

 

10,858

 

 

11,543

 

 

48,409

 

 

43,989

 

 

44,178

 

 

Advertising and promotion expenses

 

 

6,313

 

 

6,606

 

 

41,420

 

 

33,854

 

 

115,478

 

 

General and administrative expenses

 

 

7,685

 

 

9,493

 

 

28,261

 

 

24,509

 

 

25,455

 

 

Impairment of goodwill

 

 

-

 

 

-

 

 

1,440

 

 

-

 

 

-

 

 

Impairment loss from assets disposal

 

 

-

 

 

(80)

 

 

-

 

 

5,894

 

 

-

 

 

Other operating income, net

 

 

957

 

 

396

 

 

1,441

 

 

894

 

 

5,790

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(6,431)

 

 

11,773

 

 

(40,342)

 

 

(23,942)

 

 

(125,879)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

2,920

 

 

2,386

 

 

10,321

 

 

8,603

 

 

4,857

 

 

Interest income

 

 

388

 

 

246

 

 

820

 

 

1,850

 

 

341

 

 

Other income (expense), net

 

 

(21)

 

 

10

 

 

277

 

 

(1,081)

 

 

(580)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before income tax benefit

 

 

(8,984)

 

 

9,643

 

 

(49,566)

 

 

(31,776)

 

 

(130,975)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax benefit

 

 

(384)

 

 

593

 

 

(9,306)

 

 

(6,904)

 

 

(30,386)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(8,600)

 

 

9,050

 

 

(40,260)

 

 

(24,872)

 

 

(100,589)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to the noncontrolling interest

 

 

(61)

 

 

(28)

 

 

(192)

 

 

(257)

 

 

(40)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to Synutra International, Inc. 
common shareholders

 

$

 

(8,539)

 

$

 

9,078

 

$

 

(40,068)

 

$

 

(24,615)

 

$

 

(100,549)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share - basic

 

$

 

(0.15)

 

$

 

0.17

 

$

 

(0.71)

 

$

 

(0.46)

 

$

 

(1.86)

 

 

Loss per share - diluted

 

$

 

(0.15)

 

$

 

0.17

 

$

 

(0.71)

 

$

 

(0.46)

 

$

 

(1.86)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common share outstanding - 
basic

 

 

57,301

 

 

54,001

 

 

56,476

 

 

54,001

 

 

54,001

 

 

Weighted average common share outstanding - 
diluted

 

 

57,301

 

 

54,187

 

 

56,476

 

 

54,001

 

 

54,001

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 




 

 

Synutra International, Inc.

 

 

 

 

 

 

Consolidated Balance Sheets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2011

 

 

March 31, 2010

 

 

 

(in thousands, except share par value)

 

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

 

48,741

 

$

 

48,693

 

 

Restricted cash

 

 

37,690

 

 

33,384

 

 

Accounts receivable, net of allowance

 

 

46,021

 

 

26,013

 

 

Inventories

 

 

67,372

 

 

52,134

 

 

Due from related parties

 

 

13,708

 

 

8,111

 

 

Income tax receivable

 

 

259

 

 

523

 

 

Receivable from assets disposal

 

 

1,714

 

 

5,879

 

 

Prepaid expenses and other current assets

 

 

11,562

 

 

8,209

 

 

Deferred tax assets

 

 

20,922

 

 

33,390

 

 

 

 

 

 

 

 

Total current assets

 

 

247,989

 

 

216,336

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

 

109,811

 

 

110,037

 

 

Land use rights, net

 

 

6,096

 

 

5,996

 

 

Intangible assets, net

 

 

3,140

 

 

3,394

 

 

Goodwill

 

 

-

 

 

1,437

 

 

Receivable from assets disposal

 

 

-

 

 

4,404

 

 

Other assets

 

 

4,022

 

 

3,575

 

 

Deferred tax assets

 

 

27,646

 

 

4,178

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$

 

398,704

 

$

 

349,357

 

 

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

Short-term debt

 

$

 

124,281

 

$

 

98,069

 

 

Long-term debt due within one year

 

 

38,131

 

 

61,194

 

 

Accounts payable

 

 

52,923

 

 

49,947

 

 

Due to related parties

 

 

2,330

 

 

2,670

 

 

Advances from customers

 

 

4,890

 

 

9,375

 

 

Other current liabilities

 

 

25,913

 

 

22,674

 

 

 

 

 

 

 

 

Total current liabilities

 

 

248,468

 

 

243,929

 

 

 

 

 

 

 

 

Long-term debt

 

 

62,722

 

 

41,018

 

 

Deferred revenue

 

 

4,456

 

 

4,688

 

 

Capital lease obligations

 

 

5,540

 

 

5,372

 

 

Other long-term liabilities

 

 

1,592

 

 

1,419

 

 

 

 

 

 

 

 

Total liabilities

 

 

322,778

 

 

296,426

 

 

 

 

 

 

 

 

Equity:

 

 

 

 

 

 

Synutra International, Inc. shareholders' equity

 

 

 

 

 

 

Common stock, $.0001 par value: 250,000 authorized; 57,301 
and 54,001 issued and outstanding at March 31, 2011 and 2010, 
respectively

 

 

6

 

 

5

 

 

Additional paid-in capital

 

 

135,440

 

 

76,607

 

 

Accumulated deficit

 

 

(88,357)

 

 

(48,289)

 

 

Accumulated other comprehensive income

 

 

28,204

 

 

24,015

 

 

 

 

 

 

 

 

Total Synutra common shareholders' equity

 

 

75,293

 

 

52,338

 

 

 

 

 

 

 

 

Noncontrolling interest

 

 

633

 

 

593

 

 

 

 

 

 

 

 

Total equity

 

 

75,926

 

 

52,931

 

 

 

 

 

 

 

 

TOTAL LIABILITIES AND EQUITY

 

$

 

398,704

 

$

 

349,357

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
Source: Synutra International, Inc.
Related Stocks:
NASDAQ:SYUT
Keywords: Food/Beverages
collection